Selvita S.A. (WSE:SLV)
Poland · Delayed Price · Currency is PLN 25.00
-0.40 (-1.57%)
Jul 24, 2026, 5:00 PM CET
Selvita Financials Overview
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 359.37 | 370.57 | 345.76 | 351.85 | 364.55 | 315.73 |
Revenue Growth | -0.12% | 7.17% | -1.73% | -3.48% | 15.47% | 122.46% |
Gross Profit Gross Profit Growth | 359.37 | 370.57 | 345.76 | 351.85 | 364.55 | 315.73 |
Operating Income Operating Income Growth | 3.87 | 68.98 | 55.8 | 69.31 | 39.93 | 26.09 |
Net Income Net Income Growth | 0.78 | 0.81 | -6.1 | 69.88 | 30.31 | 14.9 |
Earnings Per Share EPS Growth | -0.20 | 0.04 | -0.30 | 3.80 | 1.70 | 0.80 |
EPS Growth | - | - | - | 123.53% | 112.50% | -23.52% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Drug Discovery Drug Discovery Growth | 253.77 | 265.32 | 260.63 | 277.41 | - | - |
Drug Development Drug Development Growth | 104.88 | 103.37 | 81.87 | 67.16 | - | - |
Unallocated Revenues From The Sale of Administrative Services Unallocated Revenues From The Sale of Administrative Services Growth | 1.09 | 1.31 | 2.83 | 7.16 | - | - |
Unallocated Other Income Unallocated Other Income Growth | 1.01 | 0.99 | 0.68 | 0.37 | - | - |
Elimination of Intersegment Elimination of Intersegment Growth | - | -0 | -0.01 | - | -3.11 | -3.09 |
Total Total Growth | 360.74 | 370.99 | 346.01 | 352.11 | 364.55 | 315.73 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19.89 | 24.22 | 22.51 | 52.65 | 74.16 | 83.55 |
Total Debt Total Debt Growth | 167.93 | 169.57 | 218.54 | 224.75 | 212.97 | 179.8 |
Net Cash (Debt) Net Cash Growth | -148.04 | -145.35 | -196.03 | -172.09 | -138.81 | -96.25 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -8.06 | -7.92 | -10.68 | -9.38 | -7.56 | -5.24 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 72.18 | 73.26 | 64.07 | 78.98 | 75.43 | 85.41 |
Capital Expenditures CapEx Growth | -9.04 | -7.08 | -18.71 | -73.78 | -100.59 | -25.46 |
Free Cash Flow Free Cash Flow Growth | 63.14 | 66.18 | 45.36 | 5.2 | -25.16 | 59.95 |
Free Cash Flow Growth | 38.49% | 45.89% | 772.46% | - | - | 317.67% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | 1.08% | 18.61% | 16.14% | 19.70% | 10.95% | 8.26% |
Pretax Margin | 0.22% | -0.21% | -3.02% | 19.10% | 9.63% | 6.67% |
Profit Margin | 0.22% | 0.22% | -1.76% | 19.86% | 7.76% | 5.77% |
FCF Margin | 17.57% | 17.86% | 13.12% | 1.48% | -6.90% | 18.99% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 1080.00 | - | 15.39 | 48.76 | 102.50 |
Forward PE | 28.37 | 49.66 | 49.38 | 26.70 | 22.69 | 33.23 |
P/FCF Ratio | 7.27 | 11.98 | 20.03 | 206.50 | - | 25.11 |
PS Ratio | 1.28 | 2.14 | 2.63 | 3.05 | 7.81 | 4.77 |